<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349985</url>
  </required_header>
  <id_info>
    <org_study_id>HHSN275201000011C</org_study_id>
    <secondary_id>HHSN275201000011C</secondary_id>
    <nct_id>NCT01349985</nct_id>
  </id_info>
  <brief_title>Adaptive Goal-Directed Adherence Tracking and Enhancement</brief_title>
  <acronym>AGATE</acronym>
  <official_title>SBIR-PhaseII, &quot;Adaptive Goal-Directed Adherence Tracking and Enhancement&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Talaria, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Talaria, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Talaria, Inc., has designed an adherence tracking and enhancement system, called AGATE, which&#xD;
      uses the text messaging and internet capabilities of modern cellular phones to address the&#xD;
      problem of medication adherence in clinical care and clinical trial contexts. This trial will&#xD;
      evaluate whether AGATE improves medication adherence in the context of a pharmacotherapy&#xD;
      trial of naltrexone to treat problem drinking. All participants will be treatment-seeking&#xD;
      problem drinkers who will receive naltrexone and medication monitoring over 8 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the naltrexone trial is to evaluate whether AGATE effectively measures and&#xD;
      enhances medication adherence in the context of naltrexone treatment for problem drinking.&#xD;
      Participants will be heavy/problem drinkers, recruited from the greater Albuquerque area, who&#xD;
      are interested in either reducing or stopping their drinking and deemed to be candidates for&#xD;
      naltrexone pharmacotherapy by the study psychiatrist, Dr. Arenella. All participants will be&#xD;
      prescribed naltrexone, 50 mg, once daily, for eight weeks, and receive smartphones.&#xD;
      Participants will be randomly assigned to receive either AGATE or SASED, a web-based alcohol&#xD;
      and side-effects diary via smartphone. The primary outcome will be percent of scheduled doses&#xD;
      that were taken during the eight week trial, as measured by the Medication Event Monitoring&#xD;
      System (MEMS, Aardex Group, Union City, CA), pill counts, and using the timeline follow-back&#xD;
      (TLFB) method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>8 weeks</time_frame>
    <description>Adherence will be measured using the medication event monitoring system (MEMS), pill counts, and multiple self-report indices.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Indices of alcohol use, craving, etc.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Indicies of alcohol use, cravings etc will be measured using validated patient self report measures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>AGATE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate whether AGATE, a smartphone medication reminder and assessment system, effectively measures and enhances medication adherence in the context of naltrexone treatment for problem drinking.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SASED</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control condition for the proposed study is a smartphone alcohol and side-effects diary (SASED, a smartphone alcohol and side effects diary).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AGATE</intervention_name>
    <description>AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.</description>
    <arm_group_label>AGATE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SASED</intervention_name>
    <description>Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.</description>
    <arm_group_label>SASED</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  problem or heavy drinkers&#xD;
&#xD;
          -  age 21-55 years old&#xD;
&#xD;
          -  located in the greater Albuquerque NM area&#xD;
&#xD;
          -  interested in either reducing or stopping their drinking&#xD;
&#xD;
          -  candidates for naltrexone pharmacotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  participation in other naltrexone study&#xD;
&#xD;
          -  unable to operate a smartphone&#xD;
&#xD;
          -  significant psychiatric or physical illness&#xD;
&#xD;
          -  current drug dependence&#xD;
&#xD;
          -  current regular opioid use&#xD;
&#xD;
          -  any recent nonmedical opioid use&#xD;
&#xD;
          -  any lifetime opioid dependence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Stoner, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Talaria, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Mind Research Network, University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Naltrexone</keyword>
  <keyword>problem drinking</keyword>
  <keyword>medication adherence</keyword>
  <keyword>adherence</keyword>
  <keyword>smartphone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

